Back HIV Treatment Experimental HIV Drugs

Experimental HIV Drugs

FDA Approves Descovy TAF Combination Pill for HIV Treatment, Not Yet for PrEP

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' Descovy, a new combination pill containing tenofovir alafenamide (TAF), which is easier on the kidneys and bones than the older tenfovir disiproxil fumarate (TDF) version. The new coformulation is similar to Truvada, but it has been approved only for use as a component of HIV treatment, not for pre-exposure prophylaxis or PrEP.

alt

Read more:

CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention

Merck's MK-8591, n investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to 6 months after dosing could represent a "paradigm shift" in HIV therapy and prophylaxis, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

alt

Read more:

FDA Approves Second TAF-Containing Single-Tablet HIV Regimen

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' new once-daily single-tablet regimen Odefsey, containing the NNRTI rilpivirine (developed by Janssen), emtricitabine, and tenofovir alafenamide or TAF, a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate or TDF.

alt

Read more:

CROI 2016: Combination Inhibitor BMS-986197 Demonstrates Good Anti-HIV Activity in Early Study

A long-acting bioengineered "combinectin" molecule with a triple mechanism of action demonstrated potent antiviral activity and worked against HIV that developed resistance to any of the 3 separate mechanisms in a laboratory study, and lowered viral load in humanized mice, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

Read more:

CROI 2016: TAF/FTC Maintains Viral Suppression as Well as TDF with Less Bone and Kidney Toxicity

A fixed-dose coformulation of tenofovir alafenamide (TAF) and emtricitabine (FTC), combined with a variety of third antiretroviral agents, maintained undetectable viral load in people who switched from similar regimens containing the older tenofovir disoproxil fumarate (TDF), according to a report presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)this week in Boston. The study also showed improvement in kidney function biomarkers and bone density gains in the group taking TAF/FTC.

alt

Read more: